Wattana Karnpaet PCLBKK:NEW 83 Return-on-Tangible-Equity is 5.45% as of Mar. 2026, which is 2% above its 10-year median of 5.32. GuruFocus rates BKK:NEW with a GF Score™ of 83/100 and a GF Value™ of ฿97.01 (Fairly Valued). The stock has 2 warning signs investors should review. Among 579 Healthcare Providers & Services companies, Wattana Karnpaet PCL ranks worse than 55.96% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Wattana Karnpaet PCL's annualized net income for the quarter that ended in Mar. 2026 was ฿28.7 Mil. Wattana Karnpaet PCL's average shareholder tangible equity for the quarter that ended in Mar. 2026 was ฿526.3 Mil. Therefore, Wattana Karnpaet PCL's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2026 was 5.45%.
The historical rank and industry rank for Wattana Karnpaet PCL's Return-on-Tangible-Equity or its related term are showing as below:
BKK:NEW'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: 0.46 Med: 5.32 Max: 24.14
Current: 7.89
During the past 13 years, Wattana Karnpaet PCL's highest Return-on-Tangible-Equity was 24.14%. The lowest was 0.46%. And the median was 5.32%.
BKK:NEW's Return-on-Tangible-Equity is ranked worse than 55.96% of 579
companies
in the Healthcare Providers & Services industry
Industry Median: 10.21
vs BKK:NEW: 7.89
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Wattana Karnpaet PCL Return-on-Tangible-Equity Related Terms
Wattana Karnpaet PCL Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for Wattana Karnpaet PCL's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BKK:NEW vs HCA, THC, DVA: Return-on-Tangible-Equity Comparison
For the Medical Care Facilities subindustry, Wattana Karnpaet PCL's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Wattana Karnpaet PCL Return-on-Tangible-Equity vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Wattana Karnpaet PCL's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Wattana Karnpaet PCL's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 5.45% mean?
Wattana Karnpaet PCL (BKK:NEW) has a Return-on-Tangible-Equity of 5.45% as of Mar. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Wattana Karnpaet PCL and its competitors. This is near median its historical median of 5.32. Over the past decade, Wattana Karnpaet PCL's Return-on-Tangible-Equity has ranged from 0.46 to 24.14. According to the industry distribution chart, Wattana Karnpaet PCL ranks #324 out of 579 companies in the Healthcare Providers & Services industry, placing it in the top 56%.
Is Wattana Karnpaet PCL's Return-on-Tangible-Equity too high?
Wattana Karnpaet PCL's current Return-on-Tangible-Equity of 5.45% is near median its 10-year median of 5.32. Over the past 10 years, this metric has ranged from a low of 0.46 to a high of 24.14. The Healthcare Providers & Services industry median Return-on-Tangible-Equity is 10.21. Wattana Karnpaet PCL's value of 5.45% is 46.6% below this industry median. Based on the distribution chart, Wattana Karnpaet PCL ranks #324 out of 579 companies in the Healthcare Providers & Services industry, which is below the industry midpoint. Overall, Wattana Karnpaet PCL has a GF Score™ of 83/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Wattana Karnpaet PCL's Return-on-Tangible-Equity compare to HCA and THC?
According to the Healthcare Providers & Services industry distribution chart, Wattana Karnpaet PCL ranks #324 out of 579 companies for Return-on-Tangible-Equity. This places Wattana Karnpaet PCL in the lower half of its industry. The industry median Return-on-Tangible-Equity is 10.21. Wattana Karnpaet PCL's value of 5.45% is 46.6% below this benchmark. Historically, Wattana Karnpaet PCL's own Return-on-Tangible-Equity has ranged from 0.46 to 24.14 over the past decade. While the company's 10-year median is 5.32 vs. the industry median of 10.21, Wattana Karnpaet PCL has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Healthcare Providers & Services company?
The median Return-on-Tangible-Equity among Healthcare Providers & Services companies is 10.21, based on 579 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Wattana Karnpaet PCL's current Return-on-Tangible-Equity of 5.45% is 46.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Wattana Karnpaet PCL and its competitors. For the Healthcare Providers & Services industry, the median Return-on-Tangible-Equity is 10.21 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Wattana Karnpaet PCL's current Return-on-Tangible-Equity is 5.45%, which is near median its own 10-year median of 5.32. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Wattana Karnpaet PCL stock overvalued right now?
Based on GuruFocus' analysis, Wattana Karnpaet PCL (BKK:NEW) is currently considered Fairly Valued. The stock's GF Value™ is ฿97.01, compared to a current price of ฿105.00 — trading 8.2% above its estimated fair value. The current Return-on-Tangible-Equity is 5.45%, which is near median its 10-year median of 5.32 and 46.6% below the Healthcare Providers & Services industry median of 10.21. Wattana Karnpaet PCL's overall GF Score™ is 83/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Wattana Karnpaet PCL (BKK:NEW), the current Return-on-Tangible-Equity is 5.45% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Wattana Karnpaet PCL (BKK:NEW) Overvalued in 2026?
Based on GuruFocus' analysis, Wattana Karnpaet PCL stock appears to be overvalued.
The current stock price of ฿105.00 is trading 8.2% above its estimated GF Value™ of ฿97.01.
GuruFocus considers Wattana Karnpaet PCL to be Fairly Valued.
Key valuation signals for BKK:NEW:
Return-on-Tangible-Equity: 5.45% (near median its 10-year median of 5.32)
GF Value™: ฿97.01 vs. price of ฿105.00 (8.2% above fair value)
Industry Position: 46.6% below the Healthcare Providers & Services median (#324 of 579)
No single metric tells the full story. See the BKK:NEW stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Wattana Karnpaet PCL is engaged in the operation of a hospital under the name North Eastern Wattana Hospital. It has a single segment of operation, namely the hospital and medical trading business. The company earns revenue from hospital, revenue from sales of medicines, and revenue from hospital rooms, which are derived from the provision of services to various types and a large number of customers. Geographically, the company's operations are carried out in Thailand.
83GF Score
Get the complete analysis for BKK:NEW
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BKK:NEW has been successfully added to your 
